Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

NCT06992336 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

411

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Anlotinib ,
DRUG: Benmelstobart
DRUG: Capecitabine

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University